Molecular Profile of Acute Myeloid Leukemia (AML)

Timothy A. Graubert, MD, Massachusetts General
Hospital Cancer Center, Harvard Medical School

Comprehensive studies of the acute myeloid leukemia (AML) genome have revealed new insights into the genetic basis of this disease. Recurrently mutated genes fall into pathways previously implicated in AML pathogenesis (e.g., cytokine signaling, line age specific transcription factors) and novel pathways (e.g., RNA splicing, epigenetic regulation, cohesin biology). This increased knowledge provides opportunities to refine prognostic algorithms and has identified new potential targets for therapy.